At the American Academy of Ophthalmology 2025 meeting in Orlando, Florida, Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be featuring Lacrifill Canalicular Gel, a novel therapy for dry eye symptoms, as well as sharing recently published Lacrifill patient data and patient experience study results with attendees.
“Eyecare professionals attend AAO to learn about ophthalmic innovations benefiting patients, so being able to share that 98.11% of first-time and repeat Lacrifill Canalicular Gel patients surveyed responded ‘yes’ when asked if they will come back in the future for another dose of Lacrifill Canalicular Gel is really exciting,” said Jai Parekh, MD, MBA, chief commercial officer of Eye Care U.S., in a company press release. “We are continually focused on providing data and educational opportunities showing the impact Lacrifill Canalicular Gel has on patients and practices.”
In addition, Nordic Pharma said that Vance Thompson, MD, Kayla Karpuk, OD, and Mark Packer, MD, have been invited as collaborating authors for a “Critical Perspectives” article on lacrimal occlusion in the setting of cataract and refractive surgery, which will appear in an upcoming issue of Expert Review of Ophthalmology.
“Dry eye disease can influence preoperative planning, surgical outcomes, postoperative recovery, satisfaction, and quality of life in patients undergoing premium cataract or refractive surgery," said lead author Vance Thompson in the press release. "Lacrifill fills a niche because it is indicated for up to 6 months of use, so it can be used preoperatively to optimize the ocular surface and maintain a benefit postoperatively.”
Nordic Pharma also announced that it will once again serve as the Premier Sponsor of the Women in Ophthalmology (WIO) Awards Ceremony & Networking Reception that is being held at AAO on October 18th at 5:30 p.m. In addition, the company said that AAO attendees are invited to stop by the booth for injection demonstration sessions.
Finally, the company also announced that the new TFOS Dry Eye Workshop (DEWS) III report from the Tear Film & Ocular Surface Society (TFOS), appeared in the American Journal of Ophthalmology, cited 2 studies of Nordic Pharma’s novel crosslinked hyaluronic acid (HA) canalicular filler in Section 6.2.4 Newer Plug Designs and Other Technologies. The first study found improvements in corneal staining, Schirmer test scores and other measurements 3 months after administration.
A second study, comparing Lacrifill Canalicular Gel with a commercially available hydrogel canalicular plug, found that the cross-linked HA filler is safe and well tolerated, and that “statistically significant improvements in signs and symptoms of DED were sustained through 6 months.”